BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Eviplera regulatory update

The European Commission approved Eviplera emtricitabine/rilpivirine/tenofovir disoproxil from Gilead to treat HIV-1 infection in treatment-naive adults with a viral load <=100,000 HIV-1RNA copies/mL. The...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >